|Bid||33.00 x 1000|
|Ask||34.39 x 900|
|Day's Range||34.24 - 34.81|
|52 Week Range||32.33 - 41.55|
|Beta (3Y Monthly)||0.68|
|PE Ratio (TTM)||40.83|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Frankfurt Prime Standard: QIA) today announced the publication of a multicenter clinical study demonstrating the accuracy of its QIAstat-Dx syndromic testing solution for diagnosing the causes of acute gastroenteritis. The QIAstat-Dx Gastrointestinal Panel delivered high performance compared to other, existing multiplex tests in this study which evaluated 385 patient samples at university hospital laboratories across Europe. Multiple pathogens were identified in nearly one-third of the patient samples that tested positive.
QIAGEN N.V. today announced results of operations for the second quarter of 2019, achieving the outlook set for net sales growth and adjusted earnings per share at constant exchange rates .
QIAGEN N.V. plans as previously announced to release its report on results for the second quarter and first half of 2019 on Tuesday, July 30 at approximately 22:05 Central European Time / 16:05 Eastern Standard Time .
Frankfurt Prime Standard: QIA) today announced an agreement for McKesson Medical-Surgical Inc., an affiliate of McKesson Corporation , a global leader in healthcare supply chain management solutions, to serve as the exclusive distributor of QIAGEN’s QIAstat-Dx syndromic testing solution in the “acute” market segment of U.S. hospitals with 200 beds or less and in other select segments. The agreement also makes McKesson a non-exclusive distributor for future expansion of QIAstat-Dx into the non-acute retail clinics located in U.S. retail pharmacies.
Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced the expansion of their QuantiFERON collaboration to develop an ultra-sensitive diagnostic test for Lyme disease, which is expected to address a significant unmet medical need. The QuantiFERON technology comes in two components: the QuantiFERON sample collection component with the proprietary assay stimulus/initiation and QuantiFERON read-out component to measure the signal created by the stimulus.
Innovative therascreen® PIK3CA RGQ PCR Kit receives U.S. regulatory approval for use in guiding treatment decisions from tissue and liquid biopsy for newly approved therapy PIQRAY®
New breakthrough test for low-resource, high-burden regions to help in global fight against tuberculosis
Frankfurt Prime Standard: QIA) today announced a collaboration to co-develop a diagnostic test to identify patients most likely to respond to VGX-3100, Inovio's immunotherapy to treat advanced cervical dysplasia associated with the human papillomavirus virus (HPV). This precision medicine partnership focuses on Inovio's VGX-3100, a late-stage product candidate currently in two pivotal Phase 3 clinical trials (REVEAL 1 and 2) with potential to become the first treatment for HPV infection of the cervix and the first non-surgical treatment for precancerous cervical lesions associated with the virus.
Frankfurt Prime Standard:QIA) and Inovio Pharmaceuticals Inc. (INO) today announced a collaboration to co-develop a companion diagnostic to guide clinical decision-making for the use of Inovio’s DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus (HPV). The Precision Medicine partnership focuses on Inovio’s VGX-3100, a late-stage investigational product candidate with potential to become the first treatment for HPV infection of the cervix and the first non-surgical treatment for precancerous cervical lesions associated with the virus.
QIAGEN N.V. announces that it will initiate the repurchase of a fourth tranche of shares under the share repurchase program which was announced by an ad hoc announcement dated January 31, 2018. In the time period between May 10, 2019 until June 18, 2019, at the latest, a fourth tranche of up to 2 million common shares of the Company having a total purchase price of up to USD 50 million (or the equivalent Euro amount thereof, in each case without ancillary purchasing costs) shall be repurchased exclusively on the electronic trading platform of the Frankfurt Stock Exchange (XETRA). The maximum purchase price per share (excluding ancillary purchase costs) will not exceed the average closing price for the last five trading days prior to the day of purchase on the electronic trading platform of the Frankfurt Stock Exchange by more than 10%.
QIAGEN reports results for first quarter of 2019 and announces plans for new $100 million share repurchase program
PRESS RELEASE : REGULATED INFORMATION Thursday 25 April 2019, 07:00 CEST BIOCARTIS Q1 2019 BUSINESS UPDATE Mechelen, Belgium , 25 April 2019 - Biocartis Group NV (the `Company` or `Biocartis`), an innovative ...
QIAGEN N.V. plans as previously announced to release its report on results for the first quarter 2019 on Monday, May 6 at approximately 22:05 Central European Time / 16:05 Eastern Standard Time .
Novel therascreen® FGFR RGQ RT-PCR Kit will aid in identifying patients eligible for treatment with BALVERSA™ , developed by Janssen
Frankfurt Prime Standard: QIA) today announced that its modern gold standard QuantiFERON®-TB test for detection of latent tuberculosis (TB) infections has surpassed 60 million tests administered, having impacted the lives of millions of patients worldwide and supporting the global fight against this public health issue. QIAGEN is continuing to improve and innovate with new automation options for the fourth-generation QuantiFERON®-TB Gold Plus (QFT®-Plus) test which will continue to drive rapid growth in the conversion of latent TB testing from the century-old technology of tuberculin skin tests to QIAGEN’s modern, accurate and efficient blood test.
NeuMoDx plans to deliver 11 CE-IVD assays to QIAGEN by the end of 2019 on NeuMoDx System as part of aggressive menu expansion plans, including blood-borne viruses, women’s health a
Frankfurt Prime Standard: QIA) today announced new data of the QIAstat-Dx Meningitis / Encephalitis panel. The preliminary data demonstrates effective detection of the most prevalent central nervous system pathogens with high analytical sensitivity and specificity levels, including the discrimination of clinically relevant strains and subtypes. This new test will expand the QIAGEN menu of diagnostic panels for syndromic testing, adding to CE-IVD marked DiagCORE tests for respiratory and gastrointestinal infections that were launched in 2018.
Frankfurt Prime Standard: QIA) today announced a master service agreement with LabCorp® (LH) to further accelerate the access of cancer patients to QIAGEN’s companion diagnostic products following regulatory approvals of drugs and their associated tests. As a new participant in QIAGEN’s Day-One Lab Readiness program, LabCorp will be able to provide physicians and patients with faster access to new, genomically targeted drugs that are becoming increasingly important therapies for a growing variety of cancers.
AACR 2019 includes over 30 abstracts building on QIAGEN’s Sample to Insight solutions to advance understanding of cancer and commitment to improve outcomes